Director, HEOR & RWE, Europe
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.
Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.
The Opportunity:
The Director, HEOR & RWE, Europe will lead the European HEOR and RWE strategy and execution for assigned assets, disease areas, and/or evidence-generation workstreams. The Director, HEOR & RWE, Europe will identify European evidence requirements and priorities and will work with European Medical Affairs, Global HEOR & RWE, Market Access, Clinical Development, and local affiliates to ensure that plans address regional and country needs. The role will oversee HEOR/RWE evidence generation driving
